Novel Biomarkers Related Xuebijing Injection Improves Sepsis

ConditionSepsis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorSoutheast University, China

About this trial

Sepsis is a life-threatening clinical syndrome of organ dysfunction caused by dysregulation of the body's response to infection, and is a common cause of ICU admission for critically ill patients, posing a serious threat to human health. The study demonstrated that hemopexin injection significantly reduced the 28-day all-cause mortality rate of sepsis patients, and this study clarified the specific target and molecular mechanism of hemopexin injection in the treatment of sepsis, which may be of great scientific significance and clinical value for the precise treatment of sepsis and the research and development of new drugs.

Eligibility criteria

Qualifiers

Meeting the Sepsis 3.0 diagnostic criteria;

SOFA score ≥ 2 and < 13;

Signed informed consent.

Disqualifiers

Age <18 years or >75 years;

Pregnant or lactating women;

Presence of severe primary diseases including malignant tumors severe hematologic disorders and HIV infection;

Current use of immunosuppressants or history of organ transplantation within the past 6 months;

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

30 Participants
are grouped into 3 trial groups

Locations

This trial has no locations

Sponsors and collaborators